mitomycin has been researched along with Minimal Disease, Residual in 28 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with residual tumor on posttreatment biopsy were treated with a salvage regimen that consisted of additional pelvic RT (9 Gy), 5-FU, and cisplatin (100 mg/m2)." | 2.68 | Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. ( Coia, L; Doggett, S; Flam, M; John, M; Kerman, H; Murray, K; Myerson, R; Pajak, TF; Petrelli, N; Quivey, J; Rotman, M, 1996) |
| "The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage." | 2.52 | Anal cancer treatment: current status and future perspectives. ( Abdayem, P; Antoun, J; Ghosn, M; Kourie, HR; Nasr, D, 2015) |
| "Close to 75% of all bladder tumors are confined to the urothelium (stage Ta, or carcinoma in situ), and nearly 30% of papillary tumors invade the lamina propria (stage T1)." | 2.41 | Intravesical therapy for superficial bladder cancer. ( Baselli, EC; Greenberg, RE, 2000) |
| "A pathologic cervical residual tumor was observed in 16 patients (35." | 1.43 | [Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy]. ( Ballester, M; Daraï, E; Huguet, F; Lauratet, B; Lefranc, JP; Monnier, L; Touboul, E, 2016) |
| "Pseudomyxoma peritonei is a diffuse peritoneal malignancy that generally originates form a perforated appendiceal tumor." | 1.39 | Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. ( Cecil, TD; Chandrakumaran, K; Dayal, S; Mohamed, F; Moran, BJ; Riss, S; Taflampas, P, 2013) |
| "We conclude that minimal residual disease, compared with macroscopically complete cytoreduction, correlated to failure in critical anatomical areas, suggesting the need for maximal cytoreductive surgical efforts." | 1.35 | Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). ( Baratti, D; Cabras, AD; Deraco, M; Dileo, P; Kusamura, S; Laterza, B, 2009) |
| "In phase II trials in superficial bladder cancer, marker lesions have been used to test the ablative activity of intravesical chemo- or immunotherapy." | 1.31 | Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions. ( Bono, AV; Brausi, M; de Balincourt, C; Hall, R; Mack, D; Oosterlinck, W; Sylvester, R, 2001) |
| "Mitomycin C was administered initially and mitoxantrone was administered following the same schedule if disease recurred during followup." | 1.29 | Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. ( Carmignani, G; Maffezzini, M; Raber, M; Simonato, A; Zanon, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (28.57) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 7 (25.00) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Arjona-Sanchez, A | 1 |
| Aziz, O | 1 |
| Passot, G | 1 |
| Salti, G | 1 |
| Esquivel, J | 1 |
| Van der Speeten, K | 1 |
| Piso, P | 1 |
| Nedelcut, DS | 1 |
| Sommariva, A | 1 |
| Yonemura, Y | 1 |
| Turaga, K | 1 |
| Selvasekar, CR | 1 |
| Rodriguez-Ortiz, L | 1 |
| Sanchez-Hidalgo, JM | 1 |
| Casado-Adam, A | 1 |
| Rufian-Peña, S | 1 |
| Briceño, J | 1 |
| Glehen, O | 1 |
| Barrak, D | 1 |
| Desale, S | 1 |
| Yoon, JJ | 1 |
| Dugan, MM | 1 |
| Kodavanti, PP | 1 |
| Sampah, ME | 1 |
| Sugarbaker, PH | 2 |
| Zahid, A | 1 |
| Clarke, L | 1 |
| Carr, N | 1 |
| Chandrakumaran, K | 2 |
| Tzivanakis, A | 1 |
| Dayal, S | 2 |
| Mohamed, F | 2 |
| Cecil, T | 1 |
| Moran, BJ | 2 |
| Taflampas, P | 1 |
| Riss, S | 1 |
| Cecil, TD | 1 |
| Ghosn, M | 1 |
| Kourie, HR | 1 |
| Abdayem, P | 1 |
| Antoun, J | 1 |
| Nasr, D | 1 |
| Monnier, L | 1 |
| Touboul, E | 1 |
| Daraï, E | 1 |
| Lefranc, JP | 1 |
| Lauratet, B | 1 |
| Ballester, M | 1 |
| Huguet, F | 1 |
| Ihemelandu, C | 1 |
| Paiva, B | 1 |
| Vidriales, MB | 1 |
| Cerveró, J | 1 |
| Mateo, G | 1 |
| Pérez, JJ | 1 |
| Montalbán, MA | 1 |
| Sureda, A | 1 |
| Montejano, L | 1 |
| Gutiérrez, NC | 1 |
| García de Coca, A | 1 |
| de Las Heras, N | 1 |
| Mateos, MV | 1 |
| López-Berges, MC | 1 |
| García-Boyero, R | 1 |
| Galende, J | 1 |
| Hernández, J | 1 |
| Palomera, L | 1 |
| Carrera, D | 1 |
| Martínez, R | 1 |
| de la Rubia, J | 1 |
| Martín, A | 1 |
| Bladé, J | 1 |
| Lahuerta, JJ | 1 |
| Orfao, A | 1 |
| San Miguel, JF | 1 |
| Barlogie, B | 1 |
| Epstein, J | 1 |
| Shaughnessy, JD | 1 |
| Baratti, D | 1 |
| Kusamura, S | 1 |
| Cabras, AD | 1 |
| Dileo, P | 1 |
| Laterza, B | 1 |
| Deraco, M | 1 |
| Kim, K | 1 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 1 |
| Han, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Roy, P | 1 |
| Serra, S | 1 |
| Kennedy, E | 1 |
| Chetty, R | 1 |
| Bentzen, AG | 1 |
| Guren, MG | 1 |
| Wanderås, EH | 1 |
| Frykholm, G | 1 |
| Tveit, KM | 1 |
| Wilsgaard, T | 1 |
| Dahl, O | 1 |
| Balteskard, L | 1 |
| Klug, C | 1 |
| Wutzl, A | 1 |
| Kermer, C | 1 |
| Ploder, O | 1 |
| Sulzbacher, I | 1 |
| Selzer, E | 1 |
| Voracek, M | 1 |
| Oeckher, M | 1 |
| Ewers, R | 1 |
| Millesi, W | 1 |
| Mawdsley, S | 1 |
| Glynne-Jones, R | 1 |
| Grainger, J | 1 |
| Richman, P | 1 |
| Makris, A | 1 |
| Harrison, M | 1 |
| Ashford, R | 1 |
| Harrison, RA | 1 |
| Osborne, M | 1 |
| Livingstone, JI | 1 |
| MacDonald, P | 1 |
| Mitchell, IC | 1 |
| Meyrick-Thomas, J | 1 |
| Northover, JM | 1 |
| Windsor, A | 1 |
| Novell, R | 1 |
| Wallace, M | 1 |
| Pelz, JO | 1 |
| Doerfer, J | 1 |
| Dimmler, A | 1 |
| Hohenberger, W | 1 |
| Meyer, T | 1 |
| Lim, ST | 1 |
| Jeong, HJ | 1 |
| Kim, DW | 1 |
| Yim, CY | 1 |
| Sohn, MH | 1 |
| Maffezzini, M | 1 |
| Simonato, A | 1 |
| Zanon, M | 1 |
| Raber, M | 1 |
| Carmignani, G | 1 |
| Furukawa, Y | 1 |
| Otani, Y | 2 |
| Ihara, A | 1 |
| Tsuji, R | 1 |
| Okamura, R | 1 |
| Sato, K | 1 |
| Hiki, Y | 1 |
| Tono, T | 1 |
| Tamaki, Y | 1 |
| Yagyu, T | 1 |
| Mishima, H | 1 |
| Nakagawa, H | 1 |
| Cho, G | 1 |
| Shin, E | 1 |
| Kobayashi, K | 1 |
| Takatsuka, Y | 1 |
| Kikkawa, N | 1 |
| Takano, S | 1 |
| Moriguchi, M | 1 |
| Seki, N | 1 |
| Higaki, T | 1 |
| Watanabe, Y | 2 |
| Takahashi, T | 1 |
| Ito, Y | 1 |
| Oishi, H | 1 |
| Nakata, Y | 1 |
| Kono, S | 1 |
| Flam, M | 1 |
| John, M | 1 |
| Pajak, TF | 1 |
| Petrelli, N | 1 |
| Myerson, R | 1 |
| Doggett, S | 1 |
| Quivey, J | 1 |
| Rotman, M | 1 |
| Kerman, H | 1 |
| Coia, L | 1 |
| Murray, K | 1 |
| Nabeya, Y | 1 |
| Okazaki, Y | 1 |
| Tohnosu, N | 1 |
| Yamazaki, M | 1 |
| Matsuda, M | 1 |
| Iizuka, H | 1 |
| Akutsu, N | 1 |
| Kono, T | 1 |
| Sato, H | 1 |
| Kubosawa, H | 1 |
| Takanishi, K | 1 |
| Matsumoto, J | 1 |
| Minami, T | 1 |
| Baselli, EC | 1 |
| Greenberg, RE | 1 |
| Oosterlinck, W | 1 |
| Bono, AV | 1 |
| Mack, D | 1 |
| Hall, R | 1 |
| Sylvester, R | 1 |
| de Balincourt, C | 1 |
| Brausi, M | 1 |
| Frucht-Pery, J | 1 |
| Rozenman, Y | 1 |
| Pe'er, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study[NCT03421132] | 250 participants (Anticipated) | Observational | 2018-02-20 | Recruiting | |||
| Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Resp[NCT00560053] | Phase 3 | 500 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment[NCT06109233] | 80 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for mitomycin and Minimal Disease, Residual
| Article | Year |
|---|---|
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Proto | 2021 |
Anal cancer treatment: current status and future perspectives.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; C | 2015 |
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic | 2000 |
5 trials available for mitomycin and Minimal Disease, Residual
| Article | Year |
|---|---|
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
[Effect of prophylactic intra-arterial infusion of anticancer drugs on post hepatic resection for hepatic metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1994 |
[Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Do | 1994 |
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 1994 |
Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; | 1996 |
20 other studies available for mitomycin and Minimal Disease, Residual
| Article | Year |
|---|---|
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Cy | 2021 |
Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Femal | 2021 |
Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Hypert | 2013 |
[Stage IB2, IIA and IIB cervical carcinoma without lymph node extension treated with neoadjuvant chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; C | 2016 |
Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2017 |
Going with the flow, and beyond, in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Mo | 2009 |
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B | 2012 |
The prognostic value of grade of regression and oncocytic change in rectal adenocarcinoma treated with neo-adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Ne | 2012 |
Preoperative radiochemotherapy and radical resection for stages II to IV oral and oropharyngeal cancer: grade of regression as crucial prognostic factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fe | 2005 |
Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Moda | 2005 |
Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Chemotherapy, Cancer, Regi | 2006 |
F-18 FDG PET-CT findings of intraperitoneal carbon particles-induced granulomas mimicking peritoneal carcinomatosis.
Topics: Adult; Carbon; Diagnosis, Differential; Extravasation of Diagnostic and Therapeutic Materials; False | 2008 |
Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Trans | 1996 |
[Home therapy approach in cancer patients-chemotherapy (case 2-1)].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac | 1994 |
Metastatic malignant meningioma of the liver with hypoglycemia: report of a case.
Topics: Aged; Chemoembolization, Therapeutic; Fatal Outcome; Hepatectomy; Humans; Hypoglycemia; Liver; Liver | 1998 |
[Management after hepatectomy of colorectal cancer metastases to the liver--intrahepatic arterial infusion chemotherapy and repeated hepatectomy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1999 |
Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitio | 2001 |
Topical mitomycin-C for partially excised conjunctival squamous cell carcinoma.
Topics: Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Conjunc | 2002 |